{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:40:14Z","timestamp":1761100814015},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,3,27]],"date-time":"2006-03-27T00:00:00Z","timestamp":1143417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>  <jats:italic>Background:<\/jats:italic>\u2002Plasma concentrations of oral busulfan (BU) were measured in multiple myeloma (MM) patients undergoing autologous peripheral blood stem cell transplantation (ASCT) with a double alkylating conditioning protocol in order to individualise doses of BU based on individual pharmacokinetic parameters and to reduce toxicities related to BU exposure. <jats:italic>Patients and methods:<\/jats:italic>\u2002Forty\u2010four consecutive patients with MM participating in the co\u2010operative Spanish protocol were prospectively evaluated. Conditioning regimen prior to autologous infusion consisted of BU followed by melphalan. BU pharmacokinetic parameters were estimated for each patient after the first dose based on measured concentrations and subsequent doses were modified as necessary to achieve target exposure. <jats:italic>Results:<\/jats:italic>\u2002Mean BU exposure (AUC<jats:sub>ss<\/jats:sub>) (\u00b1DS) before dosage modification range from 3192 to 12\u2003180\u2003ng\u2003h\/mL. Twenty\u2010six out of 44 (59%) patients required dose adjustment. None of the patients developed hepatic veno\u2010occlusive disease (VOD). Grade\u2003\u2265\u2003II oropharyngeal mucositis was observed in the majority of patients (95%) and the severity of mucositis increased with increasing average steady\u2010state BU plasma concentration. There were four treatment\u2010related deaths: two patients died from multiorgan failure and two of respiratory infections. Of the remaining 40 patients, 15 were in complete remission with negative immunofixation, 21 in partial remission and four in stable disease 3\u2003months after ASCT. <jats:italic>Conclusions:<\/jats:italic>\u2002The results of the present study show the variability in BU pharmacokinetic parameters and suggest the possible relationship between toxicities and BU exposure. Individualising BU dosage in MM patients undergoing ASCT we observed the absence of VOD.<\/jats:p>","DOI":"10.1111\/j.0902-4441.2006.t01-1-ejh2478.x","type":"journal-article","created":{"date-parts":[[2006,3,27]],"date-time":"2006-03-27T11:56:18Z","timestamp":1143460578000},"page":"1-6","source":"Crossref","is-referenced-by-count":11,"title":["Absence of veno\u2010occlussive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantation with targeted busulfan dosage"],"prefix":"10.1111","volume":"77","author":[{"given":"A.","family":"Clop\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sureda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sierra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Queralt\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Broto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Farr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Mangues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,3,27]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood.V93.12.4436","article-title":"The impact of obesity and disease on busulfan oral clearance in adults","volume":"93","author":"Gibbs JP","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809402800911"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.108"},{"key":"e_1_2_5_5_2","first-page":"843","article-title":"Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders","volume":"18","author":"Hassan M","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689702"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood.V80.9.2425.2425","article-title":"Optimization of busulfan dosage in children undergoing bone marrow9. transplantation: a pharmacokinetic study of dose escalation","volume":"80","author":"Yeager AM","year":"1992","journal-title":"Blood"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402193"},{"key":"e_1_2_5_9_2","first-page":"31","article-title":"Graft\u2010rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics","volume":"16","author":"Slattery JT","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702371"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00694339"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700994"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703047"},{"key":"e_1_2_5_14_2","first-page":"225","article-title":"Association of busulfan area under the curve with veno\u2010occlusive disease following BMT","volume":"17","author":"Dix SP","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199810000-00017"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200039020-00005"},{"key":"e_1_2_5_17_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1702561","article-title":"Individualizing high\u2010dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogenic stem cell transplantation for advanced hematologic malignancies","volume":"26","author":"Tran HT","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_5_18_2","first-page":"18","article-title":"Busulfan disposition: the role of threrapeutic monitoring in bone marrow transplantation induction regimens","volume":"20","author":"Grochow LB","year":"1993","journal-title":"Semin Oncol"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01979.x"},{"key":"e_1_2_5_20_2","first-page":"S218","article-title":"Prospects of the currents protocol of the Spanish Myeloma Group","volume":"4","author":"Lahuerta JJ","year":"2003","journal-title":"Hematol J"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(87)80531-5"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-4-199302150-00003"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(99)70006-6"},{"key":"e_1_2_5_24_2","first-page":"1562","article-title":"Regimen\u2010related toxicity in patients undergoing bone marrow transplantation","volume":"1988","author":"Bearman SI","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91548-1"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00930.x"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701001"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12374454"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2003.09.001"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2003.50029"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0902-4441.2006.t01-1-EJH2478.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0902-4441.2006.t01-1-EJH2478.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T01:43:18Z","timestamp":1696988598000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0902-4441.2006.t01-1-EJH2478.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.0902-4441.2006.t01-1-EJH2478.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0902-4441.2006.t01-1-ejh2478.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,27]]}}}